This is a Phase III randomized controlled trial protocol for adults with first-ever or recurrent minor stroke or transient ischaemic attack. The study is set in hospitals in Auckland and Hamilton, New Zealand, with a revised required sample size of 320 (total n=360). The intervention is Health and Wellness (HWC) coaching, compared to Usual Care (UC).
The primary outcome is the difference in the mean change from baseline systolic blood pressure (SBP) to 6 months post-randomisation between the UC and HWC groups. Secondary outcomes include cardiovascular health score using the Life's Simple 7, stroke awareness, quality of life, satisfaction with life, cognition, mood, medication adherence, adverse cardiovascular events, health and service costs, and productivity status. The follow-up period is 6 months post-randomisation.
No main results are reported, as the trial is a protocol and statistical analysis plan. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, are not reported. Key limitations, funding, conflicts, practice relevance, causality, and certainty notes are not reported.
Clinicians should note that this is a protocol for an ongoing trial, and no efficacy or safety findings are available. The planned comparison may inform future care for blood pressure management in this population, but evidence is not yet established.
View Original Abstract ↓
Rationale: Up to 90% of strokes are preventable through the modification and control of lifestyle risk factors. Health and Wellness (HWC) coaching is an established psychological intervention that may address multiple risk factors, including high blood pressure to reduce the risk of stroke. Aims: To determine the effectiveness of HWC in the management of blood pressure and stroke-related modifiable risk factors in reducing the risk of stroke. Methods: This Phase III, open-label, single-blinded, two-arm randomised controlled trial recruited adults with first-ever or recurrent minor stroke or transient ischaemic attack from hospitals in Auckland and Hamilton, New Zealand. Eligible participants were 18 years, independent in activities of daily living, had at least two modifiable cardiovascular risk factors, elevated or treated systolic blood pressure, were English-speaking, and had no history of major stroke, myocardial infarction, significant cognitive or mood disorders, or terminal illness. Longitudinal outcomes will be analysed using linear mixed-effects models under an intention-to-treat framework, with time-to-event outcomes analysed using competing-risk methods and missing data handled using multiple imputation with pooling based on Rubin's rules. Study outcomes: The primary outcome is difference in the mean change from baseline systolic blood pressure (SBP) to 6-months post-randomisation between control (Usual Care, UC) and HWC groups. The study (n=360) is powered 85% (two sided 0.05) to detect a mean difference in change of SBP 6 mm Hg (SD {+/-} 20 mm Hg) between HWC and UC groups at 6-months post-randomisation, accounting for a 20% attrition rate. A revised sample size calculation due to a lower attrition rate (9%) provided a required sample size of 320. Secondary outcomes include cardiovascular health score using the Life's Simple 7; stroke awareness; quality of life; satisfaction with life: cognition; mood; medication adherence; adverse cardiovascular events; health and service costs and productivity status. Discussion: HWC has the potential to modify lifestyle risk factors for stroke. This trial will be the first to test the effectiveness of HWC to modify lifestyle risk factors for secondary stroke prevention